ReviewFrontiers in neurology2025
Mechanism of the analgesic effect of electroacupuncture on bone cancer pain through the neuro-immune system: progress based on animal experiments.
Review in Frontiers in neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This article summarizes the mechanism of the analgesic effect of electroacupuncture (EA) on BCP by analyzing the progress of animal experimental research on the treatment of bone cancer pain (BCP). As a kind of chronic specific pain that both overlaps and incompletely coincides with inflammatory pain and neuropathic pain, BCP is mostly clinically treated with opioids such as morphine as the first-line analgesic for BCP, but the long-term application is prone to a series of unavoidable side-effects, such as tolerance, dependence, as well as cognitive impairment, nausea, constipation, and nephrotoxicity. Therefore, there is an urgent need to seek safer and more effective treatment measures. As a safe, reliable and consistently efficacious analgesic, EA produces analgesic effects in inflammatory pain, neuropathic pain and BCP. EA not only attenuates the nociceptive sensitization of BCP by modulating the release of nociception-related neurotransmitters and receptors in the nervous system, but also exerts analgesic effects on BCP by modulating the expression of inflammatory factors in the immune system, inhibiting glial cell activation, and T cell proliferation. At present, EA research on the analgesic mechanism of BCP has made some progress, but there are still problems that need to be solved, such as the lack of standardization of acupoints and parameters, weak clinical validation, a single research model, and limitations in the perspective of analgesic mechanism research. It is suggested that future studies should be based on databases such as AcuEBase v1.0 to develop standardized EA acupoint combinations and frequency parameters to provide a scientific basis for EA standardization. At the same time, the sample size should be expanded and the experimental design should be improved in order to promote the transformation of animal experiments into clinical applications. In addition, it should be expanded to more types of cancer bone metastasis pain models to verify the consistency of the analgesic effect of EA in different BCP models. Future studies could also explore the multi-target synergistic analgesic effects of EA from a microbial-immune axis perspective with the help of tools such as MicrobeTCM. And optimize the treatment plan of BCP through EA combined with drug therapy. It is believed that with the progress of science and technology as well as the continuous exploration of human beings, the complex mechanism of BCP will be overcome by human beings eventually.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.